Blog

A five-gene signature predicts overall survival of patients with papillary renal cell carcinoma

Apr . 05 . 2019

Brian I. Rini, MD, on Renal Cell Carcinoma: Results From the TIVO-3 Trial on Tivozanib vs Sorafenib

Apr . 04 . 2019

Brian I. Rini, MD, on Renal Cell Cancer: Risk Stratification After Resection of Localized Disease

Mar . 27 . 2019

ASCO GU 2019: When to Obtain Genetic Testing for Syndromic Renal Cell Cancer

Mar . 26 . 2019

Top Medications Used to Treat Kidney (Renal Cell Cancer)

Mar . 25 . 2019

Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC

Mar . 20 . 2019

New therapeutic target found for aggressive pediatric cancers with few treatment options

Mar . 19 . 2019

First-line Pembrolizumab Monotherapy

Mar . 19 . 2019

Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first-line pembrolizumab monotherapy in non-clear cell advanced RCC.

ASCO GU 2019: Analysis of Overall Survival Based on Early Tumor Shrinkage in the Phase III METEOR Study of Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma

Mar . 18 . 2019

ASCO GU 2019: Genetic Evolution of Metastatic Renal Cell Cancer

Mar . 18 . 2019

« Previous 1 … 51 52 53 54 55 … 57 Next »